ヘイズ ネルソンNelson Hayes

Last Updated :2024/12/16

所属・職名
大学院医系科学研究科（医）　准教授
自己紹介
I am a bioinformatician and Java programmer using a data science approach to investigate viral hepatitis and liver diseases. I use a supercomputer to analyze next-generation sequencing data and analyze experimental data using statistics and machine learning. I also develop relational and NoSQL database approaches for data management and build web applications using Java and Angular. Recently I have begun to focus on deep learning and graph analytics to identify host factors implicated in hepatitis B and C infection. In 2003, I received a PhD in biology from the Pennsylvania State University, where I studied evolutionary ecology of mating systems. In 2005, I became a postdoctoral fellow in the Kanehisa Laboratory in the Bioinformatics Center at Kyoto University, where I developed the varDB antigenic variation database to examine mechanisms of immune escape in Plasmodium falciparum and other human pathogens.

基本情報

主な職歴

  • 2009年10月01日, 2010年05月31日, 広島大学, 病院, 研究員
  • 2010年06月01日, 2012年03月31日, 広島大学, 大学院医歯薬学総合研究科, 特任助教
  • 2012年04月01日, 2013年03月31日, 広島大学, 大学院医歯薬保健学研究院, 特任助教
  • 2013年04月01日, 2014年03月31日, 広島大学, 大学院医歯薬保健学研究院, 特任講師
  • 2014年04月01日, 2014年12月31日, 広島大学, 大学院医歯薬保健学研究院, 特任准教授
  • 2015年01月01日, 2019年03月31日, 広島大学, 大学院医歯薬保健学研究院, 准教授
  • 2003年09月01日, 2004年12月31日, ペンシルバニア州立大学, 生物学科, マルチメディアサポートアシスタント
  • 2005年01月01日, 2005年10月15日, ペンシルバニア州立大学, 生物学科, 専任講師
  • 2005年10月16日, 2009年09月30日, 京都大学, 化学研究所ンター バイオインフォマティクスセ, 特定研究員、日本学術振興会研究員を含む

学歴

  • ペンシルバニア州立大学, 生物学科, 生物学, アメリカ合衆国, 1996年08月, 2003年12月
  • ワシントン・ジェファーソン大学, 生物学科, 生物学, アメリカ合衆国, 1992年08月, 1996年06月

学位

  • 博士（生物学）　(ペンシルバニア州立大学)

研究分野

  • 医歯薬学 / 基礎医学 / ウイルス学
  • 医歯薬学 / 基礎医学 / 人類遺伝学
  • 総合生物 / ゲノム科学 / ゲノム医科学
  • 情報学 / 計算基盤 / ソフトウェア
  • 情報学 / 計算基盤 / 高性能計算
  • 生物学 / 基礎生物学 / 進化生物学
  • 生物学 / 基礎生物学 / 生態・環境

研究キーワード

  • 肝炎
  • ウイルス学
  • 肝臓
  • ジャヴァ
  • 次世代シーケンシング
  • スーパーコンピュータ
  • データベース

教育活動

授業担当

  1. 2024年, 博士課程・博士課程後期, セメスター（前期）, English Presentation
  2. 2024年, 博士課程・博士課程後期, セメスター（前期）, English Presentation

研究活動

学術論文（★は代表的な論文）

  1. Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma, MEDICINE, 103巻, 34号, 20240823
    DOIを用いた論文検索結果へのリンク
  2. Multi-omics analysis of a fatty liver model using human hepatocyte chimeric mice, SCIENTIFIC REPORTS, 14巻, 1号, 20240209
    DOIを用いた論文検索結果へのリンク
  3. Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma, CANCERS, 16巻, 7号, 202404
    DOIを用いた論文検索結果へのリンク
  4. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 54巻, 2号, pp. 175-181, 20240207
    DOIを用いた論文検索結果へのリンク
  5. Clinicopathological and genomic features of superficial esophageal squamous cell carcinomas in nondrinker, nonsmoker females, CANCER MEDICINE, 13巻, 4号, 202402
    DOIを用いた論文検索結果へのリンク
  6. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma, COMMUNICATIONS MEDICINE, 3巻, 1号, 20231025
    DOIを用いた論文検索結果へのリンク
  7. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure, HEPATOLOGY INTERNATIONAL, 17巻, 5号, pp. 1225-1232, 202310
    DOIを用いた論文検索結果へのリンク
  8. Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 38巻, 9号, pp. 1637-1646, 202309
    DOIを用いた論文検索結果へのリンク
  9. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment, CANCERS, 15巻, 17号, 202309
    DOIを用いた論文検索結果へのリンク
  10. HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice, HEPATOLOGY, 78巻, 3号, pp. 929-942, 202309
    DOIを用いた論文検索結果へのリンク
  11. Deficiency of SCAP inhibits HBV pathogenesis via activation of the interferon signaling pathway, VIROLOGY, 585巻, pp. 248-258, 202308
    DOIを用いた論文検索結果へのリンク
  12. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study, BMC GASTROENTEROLOGY, 23巻, 1号, 20230628
    DOIを用いた論文検索結果へのリンク
  13. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227巻, 5号, pp. 686-695, 20230301
    DOIを用いた論文検索結果へのリンク
  14. A novel cDNA-uPA/SCID/Rag2(-/-)/Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system, JOURNAL OF VIRAL HEPATITIS, 30巻, 3号, pp. 262-272, 202303
    DOIを用いた論文検索結果へのリンク
  15. The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis, FRONTIERS IN PUBLIC HEALTH, 11巻, 20230126
    DOIを用いた論文検索結果へのリンク
  16. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors, BMC CANCER, 22巻, 1号, 20221129
    DOIを用いた論文検索結果へのリンク
  17. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma, INTERNATIONAL JOURNAL OF CANCER, 151巻, 12号, pp. 2278-2290, 20221215
    DOIを用いた論文検索結果へのリンク
  18. Road to elimination of HCV: Clinical challenges in HCV management, LIVER INTERNATIONAL, 42巻, 9号, pp. 1935-1944, 202208
    DOIを用いた論文検索結果へのリンク
  19. Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA, JOURNAL OF GENERAL VIROLOGY, 103巻, 2号, 2022
    DOIを用いた論文検索結果へのリンク
  20. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84巻, 3号, pp. 391-399, 202203
    DOIを用いた論文検索結果へのリンク
  21. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 37巻, 3号, pp. 592-599, 202203
    DOIを用いた論文検索結果へのリンク
  22. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17巻, 8号, pp. 1551-1561, 2012
    DOIを用いた論文検索結果へのリンク
  23. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53巻, 3号, pp. 439-443, 201009
    DOIを用いた論文検索結果へのリンク
  24. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54巻, 5号, pp. 872-878, 201105
    DOIを用いた論文検索結果へのリンク
  25. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54巻, 3号, pp. 781-788, 201109
    DOIを用いた論文検索結果へのリンク
  26. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54巻, 3号, pp. 408-414, 201103
    DOIを用いた論文検索結果へのリンク
  27. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 981-988, 201106
    DOIを用いた論文検索結果へのリンク
  28. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 1048-1057, 201106
    DOIを用いた論文検索結果へのリンク
  29. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations, JOURNAL OF GENERAL VIROLOGY, 92巻, pp. 1071-1081, 201105
    DOIを用いた論文検索結果へのリンク
  30. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54巻, 6号, pp. 1094-1101, 201106
    DOIを用いた論文検索結果へのリンク
  31. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55巻, 1号, pp. 11-18, 201107
    DOIを用いた論文検索結果へのリンク
  32. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 204巻, 1号, pp. 84-93, 2011
    DOIを用いた論文検索結果へのリンク
  33. Effects of Hepatitis B Virus Infection on the Interferon Response in Immunodeficient Human Hepatocyte Chimeric Mice, JOURNAL OF INFECTIOUS DISEASES, 204巻, 2号, pp. 224-228, 2011
    DOIを用いた論文検索結果へのリンク
  34. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83巻, 9号, pp. 1597-1607, 201109
    DOIを用いた論文検索結果へのリンク
  35. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers, NATURE GENETICS, 43巻, 8号, pp. 797-U108, 201108
    DOIを用いた論文検索結果へのリンク
  36. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6巻, 8号, 2011
    DOIを用いた論文検索結果へのリンク
  37. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54巻, 3号, pp. 764-771, 201109
    DOIを用いた論文検索結果へのリンク
  38. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19巻, 2号, pp. E126-E133, 201202
    DOIを用いた論文検索結果へのリンク
  39. Hepatocellular carcinoma: Towards personalized medicine, CANCER SCIENCE, 103巻, 5号, pp. 846-850, 201205
    DOIを用いた論文検索結果へのリンク
  40. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 205巻, 2号, pp. 204-210, 2012
    DOIを用いた論文検索結果へのリンク
  41. Genetics of IL28B and HCV-response to infection and treatment, NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 9巻, 7号, pp. 406-417, 201207
    DOIを用いた論文検索結果へのリンク
  42. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56巻, 2号, pp. 555-566, 201208
    DOIを用いた論文検索結果へのリンク
  43. Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication, HEPATOLOGY RESEARCH, 42巻, 9号, pp. 841-853, 201209
    DOIを用いた論文検索結果へのリンク
  44. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47巻, 7号, pp. 834-844, 201207
    DOIを用いた論文検索結果へのリンク
  45. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7巻, 10号, 2012
    DOIを用いた論文検索結果へのリンク
  46. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines, JOURNAL OF GASTROENTEROLOGY, 48巻, 1号, pp. 1-12, 201301
    DOIを用いた論文検索結果へのリンク
  47. Interleukin-28B polymorphisms and hepatitis C virus clearance, GENOME MEDICINE, 5巻, 2013
    DOIを用いた論文検索結果へのリンク
  48. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85巻, 5号, pp. 789-798, 201305
    DOIを用いた論文検索結果へのリンク
  49. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLOS ONE, 8巻, 12号, 2013
    DOIを用いた論文検索結果へのリンク
  50. A Nonsynonymous Polymorphism in Semaphorin 3A as a Risk Factor for Human Unexplained Cardiac Arrest with Documented Ventricular Fibrillation, PLOS GENETICS, 9巻, 4号, 201304
    DOIを用いた論文検索結果へのリンク
  51. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62巻, 7号, pp. 1055-1061, 201307
    DOIを用いた論文検索結果へのリンク
  52. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108巻, 9号, pp. 1464-1472, 201309
    DOIを用いた論文検索結果へのリンク
  53. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48巻, 10号, pp. 1188-1204, 201310
    DOIを用いた論文検索結果へのリンク
  54. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice, JOURNAL OF GASTROENTEROLOGY, 48巻, 11号, pp. 1259-1270, 201311
    DOIを用いた論文検索結果へのリンク
  55. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441巻, 1号, pp. 230-235, 2013
    DOIを用いた論文検索結果へのリンク
  56. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58巻, 4号, pp. 2105-2112, 201404
    DOIを用いた論文検索結果へのリンク
  57. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial, JOURNAL OF VIRAL HEPATITIS, 21巻, 5号, pp. 348-356, 201405
    DOIを用いた論文検索結果へのリンク
  58. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21巻, 9号, pp. E89-E97, 201409
    DOIを用いた論文検索結果へのリンク
  59. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population, JOURNAL OF GENERAL VIROLOGY, 95巻, pp. 1297-1306, 201406
    DOIを用いた論文検索結果へのリンク
  60. New Insight Into the Enhanced Effect of Pegylated Interferon-alpha, HEPATOLOGY, 60巻, 4号, pp. 1435-1437, 201410
    DOIを用いた論文検索結果へのリンク
  61. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 158-165, 201502
    DOIを用いた論文検索結果へのリンク
  62. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp. 1548-1556, 201412
    DOIを用いた論文検索結果へのリンク
  63. Emerging treatments for chronic hepatitis C, JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 114巻, 3号, pp. 204-215, 201503
    DOIを用いた論文検索結果へのリンク
  64. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70巻, 3号, pp. 273-287, 201503
    DOIを用いた論文検索結果へのリンク
  65. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44巻, 14号, pp. E447-E454, 201412
    DOIを用いた論文検索結果へのリンク
  66. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: Propensity score-matched analysis, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 2号, pp. 337-344, 201502
    DOIを用いた論文検索結果へのリンク
  67. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 166-174, 201502
    DOIを用いた論文検索結果へのリンク
  68. Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection, EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 9巻, 1号, pp. 21-30, 201501
    DOIを用いた論文検索結果へのリンク
  69. Hepatitis C Virus (HCV) Reactivation Caused by Steroid Therapy for Dermatomyositis, INTERNAL MEDICINE, 53巻, 23号, pp. 2689-2693, 2014
    DOIを用いた論文検索結果へのリンク
  70. Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report, TRANSPLANTATION PROCEEDINGS, 47巻, 3号, pp. 809-814, 201504
    DOIを用いた論文検索結果へのリンク
  71. Novel Robust in Vitro Hepatitis B Virus Infection Model Using Fresh Human Hepatocytes Isolated from Humanized Mice, AMERICAN JOURNAL OF PATHOLOGY, 185巻, 5号, pp. 1275-1285, 201505
    DOIを用いた論文検索結果へのリンク
  72. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay, PLOS ONE, 10巻, 6号, 2015
    DOIを用いた論文検索結果へのリンク
  73. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63巻, 3号, pp. 554-563, 201509
    DOIを用いた論文検索結果へのリンク
  74. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice, JOURNAL OF VIROLOGY, 89巻, 19号, pp. 10087-10096, 201510
    DOIを用いた論文検索結果へのリンク
  75. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 87巻, 11号, pp. 1913-1920, 201511
    DOIを用いた論文検索結果へのリンク
  76. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy, VIRUSES-BASEL, 7巻, 10号, pp. 5328-5342, 201510
    DOIを用いた論文検索結果へのリンク
  77. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72巻, 1号, pp. 91-102, 201601
    DOIを用いた論文検索結果へのリンク
  78. Early events in hepatitis B virus infection: From the cell surface to the nucleus, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31巻, 2号, pp. 302-309, 201602
    DOIを用いた論文検索結果へのリンク
  79. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice, VIRUS RESEARCH, 213巻, pp. 62-68, 2016
    DOIを用いた論文検索結果へのリンク
  80. MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 17巻, 3号, 201603
    DOIを用いた論文検索結果へのリンク
  81. HBV culture and infectious systems, HEPATOLOGY INTERNATIONAL, 10巻, 4号, pp. 559-566, 201607
    DOIを用いた論文検索結果へのリンク
  82. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy, JOURNAL OF VIRAL HEPATITIS, 23巻, 9号, pp. 708-717, 201609
    DOIを用いた論文検索結果へのリンク
  83. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 46巻, 8号, pp. 758-764, 201607
    DOIを用いた論文検索結果へのリンク
  84. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46巻, 9号, pp. 944-948, 201608
    DOIを用いた論文検索結果へのリンク
  85. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report, HEPATOLOGY RESEARCH, 46巻, 7号, pp. 707-712, 201606
    DOIを用いた論文検索結果へのリンク
  86. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51巻, 11号, pp. 1073-1080, 201611
    DOIを用いた論文検索結果へのリンク
  87. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46巻, 12号, pp. 1256-1263, 201611
    DOIを用いた論文検索結果へのリンク
  88. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21巻, 4号, pp. 307-315, 2016
    DOIを用いた論文検索結果へのリンク
  89. Hepatitis C virus treatment update - A new era of all-oral HCV treatment, ADVANCES IN DIGESTIVE MEDICINE, 3巻, 4号, pp. 153-160, 201602
    DOIを用いた論文検索結果へのリンク
  90. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214巻, 11号, pp. 1687-1694, 2016
    DOIを用いた論文検索結果へのリンク
  91. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir plus asunaprevir, EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 11巻, 2号, pp. 103-113, 201702
    DOIを用いた論文検索結果へのリンク
  92. Interferon Stimulated Genes and Innate Immune Activation Following Infection With Hepatitis B and C Viruses, JOURNAL OF MEDICAL VIROLOGY, 89巻, 3号, pp. 388-396, 201703
    DOIを用いた論文検索結果へのリンク
  93. Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89巻, 4号, pp. 665-671, 201704
    DOIを用いた論文検索結果へのリンク
  94. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12巻, 3号, 2017
    DOIを用いた論文検索結果へのリンク
  95. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52巻, 3号, pp. 366-375, 201705
    DOIを用いた論文検索結果へのリンク
  96. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 32巻, 3号, pp. 645-650, 201705
    DOIを用いた論文検索結果へのリンク
  97. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C, HEPATOLOGY RESEARCH, 47巻, 3号, pp. E5-E13, 201705
    DOIを用いた論文検索結果へのリンク
  98. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52巻, 4号, pp. 504-511, 201704
    DOIを用いた論文検索結果へのリンク
  99. Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV, EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 10巻, 6号, pp. 583-594, 2017
    DOIを用いた論文検索結果へのリンク
  100. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52巻, 6号, pp. 746-753, 201706
    DOIを用いた論文検索結果へのリンク
  101. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 6号, 201706
    DOIを用いた論文検索結果へのリンク
  102. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98巻, 5号, pp. 1040-1047, 201705
    DOIを用いた論文検索結果へのリンク
  103. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12巻, 8号, 2017
    DOIを用いた論文検索結果へのリンク
  104. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, JOURNAL OF MEDICAL VIROLOGY, 89巻, 11号, pp. 1963-1972, 201711
    DOIを用いた論文検索結果へのリンク
  105. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation, CLINICAL JOURNAL OF GASTROENTEROLOGY, 10巻, 2号, pp. 179-184, 201704
    DOIを用いた論文検索結果へのリンク
  106. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, JOURNAL OF GASTROENTEROLOGY, 52巻, 12号, pp. 1252-1257, 201712
    DOIを用いた論文検索結果へのリンク
  107. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53巻, 1号, pp. 107-118, 201801
    DOIを用いた論文検索結果へのリンク
  108. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53巻, 2号, pp. 269-280, 201802
    DOIを用いた論文検索結果へのリンク
  109. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study, JOURNAL OF GASTROENTEROLOGY, 53巻, 4号, pp. 548-556, 201804
    DOIを用いた論文検索結果へのリンク
  110. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 9号, 201709
    DOIを用いた論文検索結果へのリンク
  111. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500巻, 2号, pp. 152-157, 20180602
    DOIを用いた論文検索結果へのリンク
  112. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99巻, 8号, pp. 1058-1065, 201808
    DOIを用いた論文検索結果へのリンク
  113. Chromosomal Abnormalities in Human Lymphocytes after Computed Tomography Scan Procedure, RADIATION RESEARCH, 190巻, 4号, pp. 424-432, 201810
    DOIを用いた論文検索結果へのリンク
  114. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90巻, 12号, pp. 1834-1840, 201812
    DOIを用いた論文検索結果へのリンク
  115. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection, VIRUSES-BASEL, 10巻, 10号, 201810
    DOIを用いた論文検索結果へのリンク
  116. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25巻, 12号, pp. 1555-1564, 201812
    DOIを用いた論文検索結果へのリンク
  117. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525巻, pp. 48-61, 201812
    DOIを用いた論文検索結果へのリンク
  118. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23巻, 3号, pp. 239-248, 2018
    DOIを用いた論文検索結果へのリンク
  119. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54巻, 3号, pp. 291-296, 201903
    DOIを用いた論文検索結果へのリンク
  120. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23巻, 8号, pp. 639-646, 2018
    DOIを用いた論文検索結果へのリンク
  121. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy, CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 1巻, 5号, pp. 516-534, 201509
    DOIを用いた論文検索結果へのリンク
  122. Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP, SCIENTIFIC REPORTS, 9巻, 20190611
    DOIを用いた論文検索結果へのリンク
  123. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54巻, 7号, pp. 650-659, 201907
    DOIを用いた論文検索結果へのリンク
  124. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100巻, 7号, pp. 1123-1131, 201907
    DOIを用いた論文検索結果へのリンク
  125. Management of HCV patients in cases of direct-acting antiviral failure, EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 13巻, 9号, pp. 839-848, 20190902
    DOIを用いた論文検索結果へのリンク
  126. Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradiation therapy, JOURNAL OF GASTROENTEROLOGY, 54巻, 10号, pp. 907-915, 201910
    DOIを用いた論文検索結果へのリンク
  127. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19巻, 1号, 20191024
    DOIを用いた論文検索結果へのリンク
  128. Regression of Idiopathic Thrombocytopenic Purpura in a Patient With Eradication of Hepatitis C Virus by Direct-Acting Antivirals, HEPATOLOGY, 71巻, 1号, pp. 389-391, 202001
    DOIを用いた論文検索結果へのリンク
  129. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 2号, pp. 267-270, 202004
    DOIを用いた論文検索結果へのリンク
  130. Genomic Characterization of Non-Invasive Differentiated-Type Gastric Cancer in the Japanese Population, CANCERS, 12巻, 2号, 202002
    DOIを用いた論文検索結果へのリンク
  131. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12巻, 202005
    DOIを用いた論文検索結果へのリンク
  132. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11巻, 202005
  133. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35巻, 8号, pp. 1412-1419, 202008
    DOIを用いた論文検索結果へのリンク
  134. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection, BMC GASTROENTEROLOGY, 20巻, 1号, 20200925
    DOIを用いた論文検索結果へのリンク
  135. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1222-1233, 202011
    DOIを用いた論文検索結果へのリンク
  136. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 6号, pp. 1233-1238, 202012
    DOIを用いた論文検索結果へのリンク
  137. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1234-1243, 202011
    DOIを用いた論文検索結果へのリンク
  138. PNPLA3andHLA-DQB1polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication, JOURNAL OF GASTROENTEROLOGY, 55巻, 12号, pp. 1162-1170, 202012
    DOIを用いた論文検索結果へのリンク
  139. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28巻, 2号, pp. 400-409, 202102
    DOIを用いた論文検索結果へのリンク
  140. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222巻, 12号, pp. 2061-2070, 20201215
    DOIを用いた論文検索結果へのリンク
  141. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14巻, 1号, pp. 283-287, 202102
    DOIを用いた論文検索結果へのリンク
  142. Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis, DIGESTIVE DISEASES AND SCIENCES, 66巻, 4号, pp. 1268-1275, 202104
    DOIを用いた論文検索結果へのリンク
  143. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60巻, 6号, pp. 829-837, 2021
    DOIを用いた論文検索結果へのリンク
  144. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23巻, 2021
    DOIを用いた論文検索結果へのリンク
  145. yRibavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 92巻, 2号, pp. 210-218, 202002
    DOIを用いた論文検索結果へのリンク
  146. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559巻, pp. 78-83, 20210625
    DOIを用いた論文検索結果へのリンク
  147. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40巻, 1号, 20210626
    DOIを用いた論文検索結果へのリンク
  148. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28巻, 9号, pp. 1304-1311, 202109
    DOIを用いた論文検索結果へのリンク

著書等出版物

  1. 2019年10月24日, Hepatocellular Carcinoma, Chapter 5. The Role of Lipids in Hepatocellular Carcinoma, Codon Publications, 2019年, 2019, 単行本（学術書）, 共著, English, C. Nelson Hayes, Peiyi Zhang, and Kazuaki Chayama
    リポジトリURL

招待講演、口頭・ポスター発表等

  1. Multi-omics analysis of a human hepatocyte chimeric mouse fatty liver model and automating clinical trial matching and report generation in a cancer genome expert panel, 2024年09月27日, 招待, 英語
  2. Of mice and men: Multi-omics analysis in a human hepatocyte chimeric mouse model and tumor genome profiling at a cancer genome expert panel in Japan, 2024年06月13日, 招待, 英語, CIPHER: Center for Computational Intelligence to Predict Health and Environmental Risks, University of North Carolina, Charlotte
  3. Joint transcriptomic and metabolomic analysis in a chimeric mouse fatty liver model, Glyco-core Symposium 2024, 2024年07月16日, 通常, 英語, iGCORE: Institute for Glyco-core Research, Nagoya University, Toyoda Auditorium
  4. Transcriptomic and metabolomic analysis of growth hormone response in a fatty liver model using human hepatocyte chimeric mice, Liver Meeting, 2022年11月05日, 通常, 英語, American Association for the Study of Liver Diseases
  5. A comparison of male and female responses to inbreeding in Cucurbita texana. Poster., Hayes, C.N.,, Winsor, J.A., Stephenson, A.G., Symposium: Frontiers in Sexual Plant Reproduction in Honor of Prof. Joseph Mascarenhas, 2001年01月05日, 通常, 英語
  6. Inbreeding depression in male and female functions in Cucurbita texana., Hayes, C.N., Winsor, J.A., Stephenson, A.G., 16th Annual Penn State Symposium in Plant Physiology: Plant Reproduction 2002: From evolutionary and physiological analyses to molecular genetic studies., 2002年05月01日, 通常, 英語
  7. Male vs. female inbreeding depression in Cucurbita texana, Hayes, C.N., Winsor, J.A., Stephenson, A.G., Ecological Society of America Annual Meeting, 2002年08月01日, 通常, 英語
  8. Assessing undergraduate learning in web-based biology instruction, Cyr, R., Harris, S., Hayes, C.N. Woodward, D, National Association for Research in Science Teaching, 2002年10月01日, 通常, 英語
  9. Inbreeding depression in male and female functions in Cucurbita texana., Hayes, C.N., Winsor, J.A., Stephenson, A.G., Royal Society Discussion Meeting on Mechanisms Regulating Gene Flow in Flowering Plants. London, UK., 2002年12月15日, 通常, 英語
  10. varDB: a sequence database of protein families involved in antigenic variation in pathogens., Hayes, C.N., Diez, D., Kanehisa, M., Wahlgren, M., Wheelock, C., Goto, S., Genome Informatics Workshop 2007. Singapore, SINGAPORE., 2007年12月10日, 通常, 英語
  11. Tools for investigating mechanisms of antigenic variation: new extensions to varDB, Hayes CN, Diez D, Joannin N, Kanehisa M, Wahlgren M, Wheelock CE, Goto S, Genome Informatics Workshop 2009, Yokohama, Japan, 2009年12月06日, 通常, 英語
  12. Serum miRNAs and the hepatitis B virus life cycle, C. Nelson Hayes, Sakura Akamatsu, Masataka Tsuge, Daiki Miki, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Hidenori Ochi, Kazuaki Chayama, AASLD, 2012年11月05日, 通常, 英語
  13. Early and late changes in gene expression profiles following infection with hepatitis B or C virus in human hepatocyte chimeric mice, Hayes, C. Nelson, Sakura Akamatsu, Masataka Tsuge, Daiki Miki, Nobuhiko Hiraga, Hiromi Abe, Michio Imamura1, Shoichi Takahashi, Hidenori Ochi, Kazuaki Chayama, AALSD 2013, 2013年11月04日, 通常, 英語
  14. Challenges in somatic mutation calling in virus-induced hepatocellular carcinoma, C. Nelson Hayes, Atsushi Ono, Sakura Akamatsu, Eisuke Murakami, Hiroshi Aikata, Michio Imamura, Daiki Miki, Hidenori Ochi, and Kazuaki Chayama, JCUP V, 2014年06月14日, 招待, 英語
  15. Hepatitis B virus infection leads to activation of interferon-stimulated genes in primary cultured human hepatocytes, but infection efficiency decreases monotonically with decreasing cell density, C. Nelson Hayes, Hiromi Abe, Sakura Akamatsu, Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Daiki Miki, Hiroshi Aikata, , Hidenori Ochi, Yuji Ishida, Chise Tateno, and Kazuaki Chayama, HBV Single topic conference 2014, 2014年11月18日, 通常, 英語
  16. Hepatitis B virus infection efficiency and immune response decreases with cell density in primary cultured hepatocytes, C. Nelson Hayes, Hiromi Abe, Sakura Akamatsu, Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Daiki Miki, Hiroshi Aikata, , Hidenori Ochi, Yuji Ishida, Chise Tateno, and Kazuaki Chayama, AASLD, 2014年11月14日, 通常, 英語
  17. Characterizing the early immune response to hepatitis B virus infection using the human hepatocyte chimeric mouse model, C. Nelson Hayes, Sakura Akamatsu, Masataka Tsuge, Daiki Miki, Hiromi Abe-Chayama, Michio Imamura, Hidenori Ochi, Kazuaki Chayama, AASLD, 2017年10月22日, 通常, 英語
  18. Estimating HBV gene expression levels based on RNAseq data in a human hepatocyte chimeric mouse mode, 高効率感染細胞系と長期持続肝炎マウスモデルを用いたHBV排除への創薬研究, 2017年12月08日, 通常, 英語, 平成２９年度茶山班班会議, 広島大学大学院　消化器・代謝内科学　
  19. Prediction of hepatitis B virus co-receptors using semi-supervised learning, Peiyi Zhang、茶山 一彰, AASLSD conference 2019, 2019年11月09日, 通常, 英語, American Association for the Study of Liver Diseases

受賞

  1. 1992年09月01日, Presidential Scholarship, Washington and Jefferson College
  2. 1999年08月01日, J. Ben and Helen D. Hill graduate student award, Pennsylvania State University
  3. 1999年07月15日, Eberly College of Science Braddock Fellowship, Pennsylvania State University
  4. 2002年05月15日, Graduate Assistant Outstanding Teaching Award, Pennsylvania State University
  5. 2006年04月01日, 日本学術振興会研究員, 日本学術振興会
  6. 2009年12月16日, Best paper award, Genome Informatics Workshop
  7. 2019年11月09日, Presidential poster of distinction, American Association for the Study of Liver Diseases

外部資金

競争的資金等の採択状況

  1. 科学研究費助成事業(若手研究(B)), 次世代シーケンサーを用いたＨＣＶに対する３者併用療法中の耐性株の動態の解析, 2012年, 2013年
    関連URL

社会活動

学術雑誌論文査読歴

  1. 2024年, Cell Reports Medicine, その他, peer reviewer, 1
  2. 2024年, その他
  3. 2024年, Hepatology Research, その他, peer reviewer, 1
  4. 2024年, Cancer Science, その他, 査読者
  5. 2024年, Gut Pathogens, その他, 査読者
  6. 2024年, Communications Biology, 査読者, 1
  7. 2024年, BioMed Research International, その他, 査読者, 1
  8. 2023年, Journal of Hepatology, その他
  9. 2023年, Scientific Reports, その他